References
Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP (2000) Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60:2444–2448
Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockage in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100:4712–4717
Hanahan D (1985) Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315:115–122
Cao ZA, Daniel D, Hanahan D (2002) Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2:11
Ganss R, Limmer A, Sacher T, Arnold B, Hammerling GJ (1999) Autoaggression and tumor rejection: it takes more than self-specific T-cell activation. Immunol Rev 169:263–272
Evans SS, Wang WC, Bain MD, Burd R, Ostberg JR, Repasky EA (2001) Fever-range hyperthermia dynamically regulates lymphocyte delivery to high endothelial venules. Blood 97:2727–2733
Mihich E, Ehrke MJ (1991) Immunomodulation by anticancer drugs. In: Devita V, Hillman S, S. Rosenberg S (eds) Biologic therapy of cancer: principles and practice. Part III. Alternative strategies for biologic therapy. Lippincott, Philadelphia, pp 776–786
Ehrke MJ, Mihich E (1996) Immunopharmacology of anticancer agents. In: Hadden JW, Szentivanyi A (eds) Immunopharmacology reviews, vol 2. Plenum, New York, pp 103–127
Ujhazy P, Zaleskis G, Mihich E, Ehrke MJ, Berleth ES (2003) Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells. Cancer Immunol Immunother 52:463–472
Cowens JW, Ozer H, Ehrke MJ, Greco W, Colvin M, Mihich E (1984) Inhibition of the development of suppressor cells in culture by 4-Hydroperoxy-cyclophosphamide. J Immunol 132:95–100
Schiavoni G, Mattei F, Pucchio TD, Santini SM, Bracci L, Belardelli F, Proietti E (2000) Cyclophosphamide induced type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95:2024
Author information
Authors and Affiliations
Corresponding author
Additional information
This article forms part of the Symposium in Writing on "Cellular immunity for cancer chemoimmunotherapy" in Volume 52 (2003)
Rights and permissions
About this article
Cite this article
Mihich, E. Cellular immunity for cancer chemoimmunotherapy—an overview. Cancer Immunol Immunother 52, 661–662 (2003). https://doi.org/10.1007/s00262-003-0423-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-003-0423-6